nach oben

Clinical and Translational Oncology

Erschienen in:

14.03.2022 | Review Article

The role of the inflammasome and its related pathways in ovarian cancer

verfasst von: Chenxi Liu, Xuemei Huang, Hongling Su

Erschienen in: Clinical and Translational Oncology | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Abstract

Ovarian cancer (OC) is the most lethal tumor of the female reproductive tract and one of the most prevalent causes of death among female cancer patients. The absence of suitable procedures for early diagnosis, chemoresistance, and limited surgical debulking are all contributing to poor survival in patients. Despite aggressive treatments, the majority of patients have a recurrence within 16–22 months. Inflammasomes are multimeric protein complexes that play a major role in the innate immune system and inflammation. The overexpression of inflammasome-related pathways, including NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3), Absent in melanoma 2 (AIM2), caspase-1, and Interleukin (IL)-1 have been reported in OC patients and in vitro cell lines. Therefore, inflammasome-related genes and protein might have a role in OC pathogenesis. Considering the potential relationship between inflammasome and OC, this study aimed to provide a literature-based review to explain the role of inflammasome and inflammation in cancer progression in OC.

Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. The Lancet. 2014;384(9951):1376–88.CrossRef

Quirk J, Kupinski J. Chronic infection, inflammation, andepithelial ovarian cancer. Med Hypotheses. 2001;57(4):426–8.PubMedCrossRef

Kisielewski R, Mazurek A, Laudański P, Tołwińska A. Inflammation and ovarian cancer–current views. Ginekol Pol. 2013;84(4):293. PubMedCrossRef

Macciò A, Madeddu C. Inflammation and ovarian cancer. Cytokine. 2012;58(2):133–47.PubMedCrossRef

Hoffman HM, Broderick L. The role of the inflammasome in patients with autoinflammatory diseases. J Allergy Clin Immunol. 2016;138(1):3–14.PubMedCrossRef

Asadi G, Varmaziar FR, Karimi M, Rajabinejad M, Ranjbar S, Karaji AG, et al. Determination of the transcriptional level of long non-coding RNA NEAT-1, downstream target microRNAs, and genes targeted by microRNAs in diabetic neuropathy patients. Immunol Lett. 2021;232:20–6.PubMedCrossRef

Kantono M, Guo B. Inflammasomes and cancer: the dynamic role of the inflammasome in tumor development. Front Immunol. 2017;8:1132.PubMedPubMedCentralCrossRef

Moossavi M, Parsamanesh N, Bahrami A, Atkin SL, Sahebkar A. Role of the NLRP3 inflammasome in cancer. Mol Cancer. 2018;17(1):1–13.CrossRef

Chang C-M, Chuang C-M, Wang M-L, Yang Y-P, Chuang J-H, Yang M-J, et al. Gene set—based integrative analysis revealing two distinct functional regulation patterns in four common subtypes of epithelial ovarian cancer. Int J Mol Sci. 2016;17(8):1272.PubMedCentralCrossRef

10.

Chang C-M, Yang Y-P, Chuang J-H, Chuang C-M, Lin T-W, Wang P-H, et al. Discovering the deregulated molecular functions involved in malignant transformation of endometriosis to endometriosis-associated ovarian carcinoma using a data-driven, function-based analysis. Int J Mol Sci. 2017;18(11):2345.PubMedCentralCrossRef

11.

Su K-M, Wang P-H, Yu M-H, Chang C-M, Chang C-C. The recent progress and therapy in endometriosis-associated ovarian cancer. J Chin Med Assoc. 2020;83(3):227–32.PubMedCrossRef

12.

Chang C-M, Wang M-L, Lu K-H, Yang Y-P, Juang C-M, Wang P-H, et al. Integrating the dysregulated inflammasome-based molecular functionome in the malignant transformation of endometriosis-associated ovarian carcinoma. Oncotarget. 2018;9(3):3704.PubMedCrossRef

13.

Fucikova J, Moserova I, Urbanova L, Bezu L, Kepp O, Cremer I, et al. Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer. Front Immunol. 2015;6:402.PubMedPubMedCentralCrossRef

14.

Machado LR, Moseley PM, Moss R, Deen S, Nolan C, Spendlove I, et al. High mobility group protein B1 is a predictor of poor survival in ovarian cancer. Oncotarget. 2017;8(60):101215.PubMedPubMedCentralCrossRef

15.

Shan W, Liu J. Inflammation: a hidden path to breaking the spell of ovarian cancer. Cell Cycle. 2009;8(19):3107–11.PubMedCrossRef

16.

Keita M, Bessette P, Pelmus M, Ainmelk Y, Aris A. Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes. J Ovarian Res. 2010;3(1):1–8.CrossRef

17.

Zeisler H, Tempfer C, Joura EA, Sliutz G, Koelbl H, Wagner O, et al. Serum interleukin 1 in ovarian cancer patients. Eur J Cancer (Oxford, England: 1990). 1998;34(6):931–3.

18.

Rathinam VA, Chan FK-M. Inflammasome, inflammation, and tissue homeostasis. Trends Mol Med. 2018;24(3):304–18.PubMedPubMedCentralCrossRef

19.

Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Women’s Health. 2019;11:287.CrossRef

20.

Reid B, Permuth J, Sellers T. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14:9–32.PubMedPubMedCentralCrossRef

21.

Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteom. 2004;3(4):355–66.CrossRef

22.

Badgwell D, Bast RC Jr. Early detection of ovarian cancer. Dis Mark. 2007;23(56):397–410.CrossRef

23.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2018;68(6):394–424.

24.

Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287–99.PubMedPubMedCentralCrossRef

25.

Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol. 2012;55(1):3–23.PubMedCrossRef

26.

Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA: Cancer J Clin. 2018;68(4):284–96.

27.

McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43(5):420–32.PubMedCrossRef

28.

Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460(3):237–49.PubMedCrossRef

29.

Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9.PubMedPubMedCentralCrossRef

30.

Odicino F, Pecorelli S, Zigliani L, Creasman WT. History of the FIGO cancer staging system. Int J Gynecol Obstet. 2008;101(2):205–10.CrossRef

31.

Rajabinejad M, Ranjbar S, Afshar Hezarkhani L, Salari F, Gorgin Karaji A, Rezaiemanesh A. Regulatory T cells for amyotrophic lateral sclerosis/motor neuron disease: a clinical and preclinical systematic review. J Cell Physiol. 2020;235(6):5030–40.PubMedCrossRef

32.

Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801.PubMedCrossRef

33.

Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805–20.PubMedCrossRef

34.

Kalmarzi RN, Rajabinejad M, Lotfi R. Immune semaphorins: Crucial regulatory signals and novel therapeutic targets in asthma and allergic diseases. Eur J Pharmacol. 2020;881:173209.PubMedCrossRef

35.

Sellegounder D, Zafari P, Rajabinejad M, Taghadosi M, Kapahi P. Advanced glycation end products (AGEs) and its receptor, RAGE, modulate age-dependent COVID-19 morbidity and mortality. A review and hypothesis. Int Immunopharmacol. 2021;98:107806.PubMedPubMedCentralCrossRef

36.

Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol. 2009;10(3):241–7.PubMedPubMedCentralCrossRef

37.

Sharma D, Kanneganti T-D. The cell biology of inflammasomes: mechanisms of inflammasome activation and regulation. J Cell Biol. 2016;213(6):617–29.PubMedPubMedCentralCrossRef

38.

Fernandes-Alnemri T, Wu J, Yu J, Datta P, Miller B, Jankowski W, et al. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 2007;14(9):1590–604.PubMedCrossRef

39.

Fink SL, Cookson BT. Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell Microbiol. 2006;8(11):1812–25.PubMedCrossRef

40.

Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526(7575):660–5.PubMedCrossRef

41.

He W-T, Wan H, Hu L, Chen P, Wang X, Huang Z, et al. Gasdermin D is an executor of pyroptosis and required for interleukin-1β secretion. Cell Res. 2015;25(12):1285–98.PubMedPubMedCentralCrossRef

42.

Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, et al. Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009;183(2):787–91.PubMedCrossRef

43.

Franchi L, Eigenbrod T, Núñez G. Cutting edge: TNF-α mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J Immunol. 2009;183(2):792–6.PubMedCrossRef

44.

Swanson KV, Deng M, Ting JP-Y. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477–89.PubMedPubMedCentralCrossRef

45.

Mokhtari Y, Pourbagheri-Sigaroodi A, Zafari P, Bagheri N, Ghaffari SH, Bashash D. Toll-like receptors (TLRs): an old family of immune receptors with a new face in cancer pathogenesis. J Cell Mol Med. 2021;25(2):639–51.PubMedCrossRef

46.

da Conceição BL, Silva LM, da Silva Ramos APÁ, Piedade JB, Vidigal PVT, Traiman P, et al. Single CpG island methylation is not sufficient to maintain the silenced expression of CASPASE-8 apoptosis-related gene among women with epithelial ovarian cancer. Biomed Pharmacother. 2014;68(1):87–91.CrossRef

47.

Gurung P, Anand PK, Malireddi RS, Walle LV, Van Opdenbosch N, Dillon CP, et al. FADD and caspase-8 mediate priming and activation of the canonical and noncanonical Nlrp3 inflammasomes. J Immunol. 2014;192(4):1835–46.PubMedCrossRef

48.

Ranjan K, Pathak C. FADD regulates NF-κB activation and promotes ubiquitination of cFLIP L to induce apoptosis. Sci Rep. 2016;6(1):1–16.CrossRef

49.

Singel KL, Grzankowski KS, Khan ANH, Grimm MJ, D’Auria AC, Morrell K, et al. Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer. Br J Cancer. 2019;120(2):207–17.PubMedCrossRef

50.

Bi F, Jiang Z, Park W, Hartwich TM, Ge Z, Chong KY, et al. A benzenesulfonamide-based mitochondrial uncoupler induces endoplasmic reticulum stress and immunogenic cell death in epithelial ovarian cancer. Mol Cancer Ther. 2021;20:2398. PubMedCrossRef

51.

Lau TS, Chan L-Y, Man G-W, Wong CH, Lee J-S, Yim SF, et al. Paclitaxel induces immunogenic cell death in ovarian cancer via TLR4/IKK2/SNARE-dependent exocytosis. Cancer Immunol Res. 2020;8:1099. PubMedCrossRef

52.

Serrano-del Valle A, Anel A, Naval J, Marzo I. Immunogenic cell death and immunotherapy of multiple myeloma. Front Cell Dev Biol. 2019;7:50.PubMedPubMedCentralCrossRef

53.

Zhou J, Wang G, Chen Y, Wang H, Hua Y, Cai Z. Immunogenic cell death in cancer therapy: present and emerging inducers. J Cell Mol Med. 2019;23(8):4854–65.PubMedPubMedCentralCrossRef

54.

Fumet J-D, Limagne E, Thibaudin M, Ghiringhelli F. Immunogenic cell death and elimination of immunosuppressive cells: a double-edged sword of chemotherapy. Cancers. 2020;12(9):2637.PubMedCentralCrossRef

55.

Kielbik M, Szulc-Kielbik I, Klink M. Calreticulin—multifunctional chaperone in immunogenic cell death: potential significance as a prognostic biomarker in ovarian cancer patients. Cells. 2021;10(1):130.PubMedPubMedCentralCrossRef

56.

Zhang Y, Yang JW, Ren X, Yang J-M. NAC1 and HMGB1 enter a partnership for manipulating autophagy. Autophagy. 2011;7(12):1557–8.PubMedPubMedCentralCrossRef

57.

Li Y, Tian J, Fu X, Chen Y, Zhang W, Yao H, et al. Serum high mobility group box protein 1 as a clinical marker for ovarian cancer. Neoplasma. 2014;61(5):579–84.PubMedCrossRef

58.

Heath O, Berlato C, Maniati E, Lakhani A, Pegrum C, Kotantaki P, et al. Chemotherapy induces tumor-associated macrophages that aid adaptive immune responses in ovarian cancer. Cancer Immunol Res. 2021;9(6):665.PubMedPubMedCentralCrossRef

59.

Wu H, Liu J, Zhang Y, Li Q, Wang Q, Gu Z. miR-22 suppresses cell viability and EMT of ovarian cancer cells via NLRP3 and inhibits PI3K/AKT signaling pathway. Clin Transl Oncol. 2021;23(2):257–64.PubMedCrossRef

60.

Hsu P-C, Chao T-K, Chou Y-C, Yu M-H, Wang Y-C, Lin Y-H, et al. AIM2 inflammasome in tumor cells as a biomarker for predicting the treatment response to antiangiogenic therapy in epithelial ovarian cancer patients. J Clin Med. 2021;10(19):4529.PubMedPubMedCentralCrossRef

61.

Wang X, Wang S-S, Zhou L, Yu L, Zhang L-M. A network-pathway based module identification for predicting the prognosis of ovarian cancer patients. J Ovarian Res. 2016;9(1):1–8.PubMedPubMedCentralCrossRef

62.

Li B-Y, Mohanraj D, Olson MC, Moradi M, Twiggs L, Carson LF, et al. Human ovarian epithelial cancer cells cultured in vitro express both interleukin 1α and β genes. Can Res. 1992;52(8):2248–52.

63.

Guo B, Fu S, Zhang J, Liu B, Li Z. Targeting inflammasome/IL-1 pathways for cancer immunotherapy. Sci Rep. 2016;6(1):1–12.

64.

Woolery KT, Mohamed M, Linger RJ, Dobrinski KP, Roman J, Kruk PA. BRCA1 185delAG mutation enhances interleukin-1β expression in ovarian surface epithelial cells. BioMed Res Int. 2015;2015:1.CrossRef

65.

Li J, Yang C, Li Y, Chen A, Li L, You Z. LncRNA GAS5 suppresses ovarian cancer by inducing inflammasome formation. Biosci Rep. 2018.https://doi.org/10.1042/BSR20171150. CrossRefPubMedPubMedCentral

66.

Luborsky J, Barua A, Edassery S, Bahr JM, Edassery SL. Inflammasome expression is higher in ovarian tumors than in normal ovary. PloS One. 2020;15(1):e0227081.PubMedPubMedCentralCrossRef

67.

Terasawa K, Sagae S, Toyota M, Tsukada K, Ogi K, Satoh A, et al. Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer Res. 2004;10(6):2000–6.PubMedCrossRef

68.

69.

Nossa CW, Jain P, Tamilselvam B, Gupta VR, Chen L-F, Schreiber V, et al. Activation of the abundant nuclear factor poly (ADP-ribose) polymerase-1 by Helicobacter pylori. Proc Natl Acad Sci. 2009;106(47):19998–20003.PubMedPubMedCentralCrossRef

70.

Sakamoto K, Tominaga Y, Yamauchi K, Nakatsu Y, Sakumi K, Yoshiyama K, et al. MUTYH-null mice are susceptible to spontaneous and oxidative stress–induced intestinal tumorigenesis. Can Res. 2007;67(14):6599–604.CrossRef

71.

Russo MT, De Luca G, Degan P, Parlanti E, Dogliotti E, Barnes DE, et al. Accumulation of the oxidative base lesion 8-hydroxyguanine in DNA of tumor-prone mice defective in both the Myh and Ogg1 DNA glycosylases. Can Res. 2004;64(13):4411–4.CrossRef

72.

Dluzniewski PJ, Wang M-H, Zheng SL, De Marzo AM, Drake CG, Fedor HL, et al. Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence. Cancer Epidemiol Prev Biomark. 2012;21(10):1774–82.CrossRef

73.

Kidane D, Chae WJ, Czochor J, Eckert KA, Glazer PM, Bothwell ALM, et al. Interplay between DNA repair and inflammation, and the link to cancer. Crit Rev Biochem Mol Biol. 2014;49(2):116–39.PubMedPubMedCentralCrossRef

74.

Ju M, Bi J, Wei Q, Jiang L, Guan Q, Zhang M, et al. Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer. Brief Bioinform. 2021;22(4):bbaa345.PubMedCrossRef

75.

Saponaro C, Scarpi E, Sonnessa M, Cioffi A, Buccino F, Giotta F, et al. Prognostic value of NLRP3 inflammasome and TLR4 expression in breast cancer patients. Front Oncol. 2021;11:705331.PubMedPubMedCentralCrossRef

76.

Burns B, Grindlay K, Dennis A. Women’s awareness of, interest in, and experiences with long-acting reversible and permanent contraception. Womens Health Issues. 2015;25(3):224–31.PubMedCrossRef

77.

Yin S, Lan C, Pei H, Zhu Z. Expression of interleukin 1β in gastric cancer tissue and its effects on gastric cancer. Onco Targets Ther. 2016;9:31.PubMed

78.

Chen LC, Wang LJ, Tsang NM, Ojcius DM, Chen CC, OuYang CN, et al. Tumour inflammasome-derived IL-1β recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma. EMBO Mol Med. 2012;4(12):1276–93.PubMedPubMedCentralCrossRef

79.

Holen I, Lefley DV, Francis SE, Rennicks S, Bradbury S, Coleman RE, et al. IL-1 drives breast cancer growth and bone metastasis in vivo. Oncotarget. 2016;7(46):75571.PubMedPubMedCentralCrossRef

80.

Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, et al. Glyburide inhibits the cryopyrin/Nalp3 inflammasome. J Cell Biol. 2009;187(1):61–70.PubMedPubMedCentralCrossRef

81.

Marchetti C, Toldo S, Chojnacki J, Mezzaroma E, Liu K, Salloum FN, et al. Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and non-ischemic injury in the mouse. J Cardiovasc Pharmacol. 2015;66(1):1.PubMedPubMedCentralCrossRef

82.

Kuwar R, Rolfe A, Di L, Xu H, He L, Jiang Y, et al. A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury. J Neuroinflammation. 2019;16(1):1–14.CrossRef

83.

Liu W, Guo W, Wu J, Luo Q, Tao F, Gu Y, et al. A novel benzo [d] imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome. Biochem Pharmacol. 2013;85(10):1504–12.PubMedCrossRef

84.

Juliana C, Fernandes-Alnemri T, Wu J, Datta P, Solorzano L, Yu J-W, et al. Anti-inflammatory compounds parthenolide and Bay 11–7082 are direct inhibitors of the inflammasome. J Biol Chem. 2010;285(13):9792–802.PubMedPubMedCentralCrossRef

85.

Rudolphi K, Gerwin N, Verzijl NVD, van der Kraan PVD, Van Den Berg W. Pralnacasan, an inhibitor of interleukin-1β converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthr Cartil. 2003;11(10):738–46.CrossRef

86.

Wannamaker W, Davies R, Namchuk M, Pollard J, Ford P, Ku G, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3, 3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R, 3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1β and IL-18. J Pharmacol Exp Ther. 2007;321(2):509–16.PubMedCrossRef

87.

Krishnan N, Bencze G, Cohen P, Tonks NK. The anti-inflammatory compound BAY-11-7082 is a potent inhibitor of protein tyrosine phosphatases. FEBS J. 2013;280(12):2830–41.PubMedPubMedCentralCrossRef

88.

Coll RC, Hill JR, Day CJ, Zamoshnikova A, Boucher D, Massey NL, et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat Chem Biol. 2019;15(6):556–9.PubMedCrossRef

89.

He Y, Varadarajan S, Muñoz-Planillo R, Burberry A, Nakamura Y, Núñez G. 3, 4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem. 2014;289(2):1142–50.PubMedCrossRef

90.

Huang Y, Jiang H, Chen Y, Wang X, Yang Y, Tao J, et al. Tranilast directly targets NLRP 3 to treat inflammasome-driven diseases. EMBO Mol Med. 2018;10(4):e8689.PubMedPubMedCentralCrossRef

91.

Jiang H, He H, Chen Y, Huang W, Cheng J, Ye J, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017;214(11):3219–38.PubMedPubMedCentralCrossRef

92.

Marchetti C, Swartzwelter B, Gamboni F, Neff CP, Richter K, Azam T, et al. OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci. 2018;115(7):E1530–9.PubMedPubMedCentralCrossRef

93.

He H, Jiang H, Chen Y, Ye J, Wang A, Wang C, et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun. 2018;9(1):1–12.CrossRef

94.

Yin Q, Sester DP, Tian Y, Hsiao Y-S, Lu A, Cridland JA, et al. Molecular mechanism for p202-mediated specific inhibition of AIM2 inflammasome activation. Cell Rep. 2013;4(2):327–39.PubMedPubMedCentralCrossRef

Titel: The role of the inflammasome and its related pathways in ovarian cancer
verfasst von: Chenxi Liu
Xuemei Huang
Hongling Su
Publikationsdatum: 14.03.2022
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 8/2022
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-022-02805-y

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

The role of the inflammasome and its related pathways in ovarian cancer

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2022

Research progress on epigenetics of small B-cell lymphoma

Accelerated partial breast irradiation (APBI)

Evidence-based guidelines for hypofractionated radiation in breast cancer: conclusions of the Catalan expert working group

P3H4 and PLOD1 expression associates with poor prognosis in bladder cancer

European clinical practice guidelines on the use of chemotherapy for advanced oesophageal and gastric cancers: a critical review using the AGREE II and the AGREE-REX instruments

Follow-up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensus

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie